RESOURCES

/

FIND A SPECIALIST

/

CONTACT

Currently Enrolling
1

OMS721 for Patients with IgAN

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Breve descripción

This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.

Médico del ensayo / Coordinador del estudio

Kien Nguyen

Correo electrónico Teléfono
Patrocinador

Omeros Corporation

Fármaco del estudio

OMS721

Matrícula estimada

430

Fecha de finalización estimada

April 2023

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Encuentre otras ubicaciones para esta prueba:
Actualmente inscribiéndose
1

OMS721 for Patients with IgAN

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

Breve descripción

This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.

La prueba es para personas con

IgA Nephropathy

Objetivo del estudio

To determine if OMS721 reduces proteinuria in patients with IgAN.

¿Qué implica para el paciente?

Patients will be involved with the trial for about 2 years, and will take either the study medication or the placebo.

Sobre el medicamento o la intervención

MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system.

Encuentre otras ubicaciones para esta prueba:
Kansas City, MO
Preguntas frecuentes

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

Ver otras preguntas frecuentes